MYC p.S146L

CI-VAR-00005033Explore in graph →CIViC 5333

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
MYC p.S146L	(oncogenic)	Oncogenic	C	Supports Oncogenicity	2	submitted	EID12696 MYC p.S146L, a recurrent substitution in the N-terminal transactivation domain near Myc Box 2, increased MYC–TRRAP binding in quantitative interaction assays and co-immunoprecipitation, with significa… (full text at CIViC) PMID 36018850 · Hinds et al., 2022 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.